DISCLAIMER: This note is intended for US recipients only and, in particular, is not directed at, nor intended to be relied upon by any UK recipients. Any information or analysis in this note is not an offer to sell or the solicitation of an offer to buy any securities. Nothing in this note is intended to be investment advice and nor should it be relied upon to make investment decisions. Read our full disclaimer, here.

I Read the Chart, Not the News

A mistake, that might not be so bad......... I hope.

BioNTech (BNTX) reported its fourth quarter and full year 2025 financial results on March 10, 2026, marking a pivotal moment in the company's evolution from a COVID-19 vaccine leader to a diversified oncology powerhouse.

Quarterly Updates

• Q4 revenues declined year-over-year to roughly $1.06 billion as the COVID-19 vaccine franchise continued its sales contraction.
• Represents a 14% decline from Q4 2024.

Year End Updates

• Full year revenues rose modestly to approximately $3.3 billion (€2.9 billion), supported by a landmark $11.1 billion collaboration agreement with Bristol Myers Squibb (BMS)
• Ended 2025 with a $19 billion cash position

Most notably,  the announcement that co-founders Prof. Ugur Sahin and Prof. Özlem Türeci plan to transition out of their executive roles to establish an independent mRNA-focused biotechnology company, a move that introduces near-term leadership uncertainty.  BioNTech plans to contribute related rights and mRNA technologies to the new company in exchange for a minority stake plus milestones and royalties. A binding agreement is expected within the first half of 2026, with the founders transitioning out by the end of 2026.

What else does 2026 have in store for BioNTech? Let's have a look.